Descartes-11 Trial Tests RNA-Engineer Cell Therapy in Multiple Myeloma
Cartesian Therapeutics launches a trial of Descartes-11, which is designed to express CAR-T molecules transiently.
Cartesian Therapeutics launches a trial of Descartes-11, which is designed to express CAR-T molecules transiently.
Find detailed drug treatment regimens for multiple myeloma, including primary therapy for both transplant candidates and non-transplant candidates.
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.
Researchers determined the impact of mutations in the CALR gene on thrombotic risk for patients with essential thrombocythemia.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.